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Abstract 
The purpose of this study was to determine the efficacy of one-year treatment of diabetic macular edema 
(DME) with intravitreal aflibercept (IVA) injections on a practical protocol and to evaluate for predictive 
factors of BCVAs at 12 months after the IVA. We reviewed the medical records of 51 eyes of 43 patients 
who were diagnosed with DME and had received IVA treatments. The best-corrected visual acuity (BCVA) 
and the central macular thickness (CMT) were measured at the baseline and at 1, 3, 6, and 12 months after 
the IVA. The mean number of IVA injections was 3.8±2.4. The changes of mean BCVA was significantly 
better (at 12months P＝0.0013) and the changes of CMT was better after the IVA at all follow up times (at 
12months P＜0.0001). The changes of BCVA was better in eyes with a serous retinal detachment (SRD) 
than without a SRD (Repeated measured ANOVA P = 0.0041). There was a significant correlation 
between the photoreceptor outer segment (PROS) length and BCVA at the baseline(P = 0.0399) and at 12 
months after the IVA (P = 0.0192 ). A fewer number of IVA injections could significantly improved the 
BCVA and the CMT in eyes with DME after one-year treatment. The IVA treatment was more effective in 
the SRD+ group than in the SRD- group. The PROS length can be a predictive marker for visual outcomes 
after one-year treatment with IVA for DME (IRB#2272). 
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Introduction 
 
Diabetic macular edema (DME) is a one of the major causes of moderate vision decrease in patients with 
non-proliferative diabetic retinopathy [1]. The result of a recent meta-analysis of 22,896 individuals with 
diabetes (META-EYE Study) found that the prevalence of DME was 6.81% which was comparable to that 
of proliferative diabetic retinopathy (6.96%) [2]. The results of several clinical trials strongly show that 
repeated injections of vascular endothelial growth factor (VEGF) antibodies improved the visual acuities 
significantly in eyes with DME [3-10]. On the other hand, medicine charge of anti-VEGF drug is very 
expensive and so the medical cost of frequent anti-VEGF injections is very high. Therefore expensive 
injection cost prohibits most patients from receiving frequent injections [11]. 
 
We have recently examined real-world data (not clinical test, under the practical medical scene’s result) on 
the efficacy of 6 months of IVA treatments in eyes with DME [12]. The results indicated that a lower 
number of IVA injections than clinical test’s that given on a practical protocol significantly improved the 
visual acuity in eyes with DME [12]. In this one-year study, we examine the efficacy of longer period of 
IVA injections in eyes with DME. In addition, we compare the efficacy of IVA in eyes with and without a 
serous retinal detachment (SRD). Because the conclusions of the efficacy of anti-VEGF injections in eyes 
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with or without SRD are still controversial [12-14]. 
 
The results of many recent studies indicated that the changes in the microstructures of the foveal 
area are correlated with the visual acuity in eyes with DME [15-20]. For example, Mori et al. 
suggested that the transverse length of the ellipsoid zone (EZ) of the photoreceptors is 
significantly correlated with the visual acuity improvement after ranibizumab injections in eyes 
with DME [15]. Shin et al. demonstrated that the preservation of the EZ and external limiting 
membrane (ELM) were associated with better visual acuity in eyes with DME [16]. The results of 
another recent study suggested that the photoreceptor outer segment (PROS) length was 
significantly correlated with the visual acuity in eyes with DME [17]. Another recent study suggests 
that the PROS length’s shortening is related to vision loss in eyes with ischemic DME [18]. Shino 
et al. indicate that PROS length is a predictive marker of postoperative visual acuities in patients 
with idiopathic epiretinal membrane [19]. Kogo et al. suggest that PROS length is a predictor of 
visual outcome in patients with DME after vitrectomy [20]. However, we did not extract any 
publications from search of PubMed that examined the correlation between the PROS length and 
outer retinal thickness with the visual acuity before and after IVA treatments in eyes with DME. 
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Thus, the purpose of this study is to determine whether the outer retinal thickness and the PROS 
length are significantly correlated with the visual acuity at 1-year after IVA treatment in eyes with 
DME.  
 
Patients and Methods 
 
The medical records of 51 eyes of 43 consecutive patients who were diagnosed with DME and 
had received IVA treatment at the Chiba University Hospital from December 2014 to February 
2016 were reviewed. Patients with DME who had a reduction of visual acuities and a central 
macular thickness (CMT) is over 250 µm based on the optical coherence tomographic images 
(SD-OCT, Heidelberg Engineering, Heidelberg, Germany) were included in this study [10]. When 
the fovea is involved in the edema, patients with focal macular edema were included. Eyes with a 
CMT <250 µm, and the following were excluded : an epiretinal membrane, vitreomacular traction, 
uveitis, glaucoma, other retinal diseases, patients with prior brain ischemia or ischemic heart 
diseases [10]. In addition, patients who did not agree with the high medicine cost of IVA treatment 
could not include in this study. The injection protocol was 1 to 3 consecutive monthly injections, 
after that we continued regular follow-up. When the CMT was over 300 µm, additional injections 
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were given. If the patients did not agree to the injection, other therapies like vitrectomy and 
sub-Tenon’s capsule triamcinolone acetonide injection were given. 
 
All of the procedures conformed to the tenets of the World Medical Association Declaration of 
Helsinki. A written informed consent was obtained from all patients and approved for this study 
was obtained from the Institutional Review Board of the Graduates School of Medicine, Chiba 
University, Japan (number 2272). 
 
The best-corrected visual acuity (BCVA) and the CMT were measured at the baseline and at 1, 3, 
6, and 12 months after the IVA injections. The BCVA was expressed in logMAR (mean ± standard 
deviation). The presence of a SRD was determined by the detection of subretinal fluid between 
the retinal pigment epithelium (RPE) and the retina in the optical coherence tomographic images. 
A SRD was present (SRD+) in 16 eyes and not present (SRD-) in 35 eyes in the IVA group. The 
patients’ data and clinical features are presented in Table 1. Furthermore, the full list of all cases is 
presented in the supplemental table. Because of the retrospective nature of the study, only eleven 
patients were treatment-naïve in this study. 
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Twenty-nine eyes had no disruption of the EZ (EZ+) and 22 eyes had a disruption of the EZ line 
(EZ-) before the IVA treatment. There were no sight threatening adverse events after the IVA 
injections. 
 
The PROS length and outer retinal thickness were measured in the cross-sectional OCT images 
and macular MAP programs. The PROS length was defined as the distance between the EZ line 
to the highly reflective RPE line and the outer retinal thickness was defined as the distance from 
the ELM to the RPE line (Figure 1). The outer retinal thickness is average thickness of central 
macular 1mm area and it was automatically measured by the embedded software in the SD-OCT.  
The PROS length was measured manually with post processing image alignment. The examiner 
measured the PROS lengths at the fixation point and at 0.5 mm from the fixation point 2 times and 
the average was used for the statistical analyses. When the foveal center could not detect 
because of severe macular edema, the fixation points were regarded as the center of the macula. 
In cases of EZ- group, there were no patients whose EZ lines were completely disappeared in this 
study. So we could draw the provisional EZ lines manually from the residual EZ lines and 
measured the PROS length. In the case of eyes with a SRD, the OCT images recorded before the 
development of a SRD or the first signs of an improvement of the SRD after the IVA treatment 
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were used for the PROS length measurements. Otherwise, the PROS length and outer retinal 
thickness were measured just before the IVA treatment. 
 
The data are presented as the means ± standard deviations or standard errors. The statistical 
analyses were performed by Wilcoxon rank test, Mann-Whitney U-test, repeated measured 
analysis of variance (ANOVA) and Spearman rank correlation with Stat View 5.0 software. A P 
<0.05 was considered significant. 
 
Results 
 
The BCVAs were significantly better at 1, 3, 6, and 12 months than at the baseline after the IVA 
injections (P = 0.0008, 0.0144, 0.0035, and 0.0013, respectively; Figure 2, Table 2). In the SRD+ 
group, the BCVAs were significantly better at 1, 3, 6, and 12 months than at the baseline after the 
IVA injections (P = 0.0176, 0.0166, 0.0021, and 0.0075, respectively; Figure 2). In the SRD- group, 
the BCVAs were significantly better only at 1 month after the IVA injections (P = 0.0227; Figure 2). 
Repeated measured ANOVA showed a significant difference in the BCVA between the SRD+ and 
SRD- groups (P = 0.0041). Thus, the BCVAs improved more significantly in the SRD+ group than 
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in the SRD- group after the IVA injections. 
 
The mean CMT was significantly reduced at 1, 3, 6, and 12 months from that at the baseline after 
the IVA injections (P <0.0001 for all; Figure 3, Table 3). In the SRD+ group, the mean CMT was 
significantly reduced at 1, 3, 6, and 12 months after the IVA (P = 0.0009, 0.0016, 0.0052, and 
0.0097, respectively; Figure 3). In the SRD- group, the mean CMT was also significantly reduced 
at 1, 3, 6, and 12 months after the IVA (P < 0.0001 for all; Figure 3). Repeated measured ANOVA 
showed that the difference in the CMT between the SRD+ and SRD- groups was not significant (P 
= 0.0914). 
 
The coefficient of correlation between outer retinal thickness and PROS length was significant at 
the baseline (= 0.374; P = 0.0086; n = 51). The coefficients of correlation between the PROS 
length before the IVA injections and the BCVAs before the IVA injections and the BCVAs 12 
months after the IVA were significant ( = -0.281, P = 0.0399, n = 51;  = -0.321, P = 0.0192, n = 
51, respectively). Thus, the PROS length before the IVA injections was significantly correlated 
with the BCVAs at 12 months after the IVA injections. On the other hand, the correlation between 
the outer retinal thickness before the IVA injections and the BCVAs before and 12 months after the 
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IVA were not significant ( = -0.109, P = 0.3969, n = 51;  = -0.095, P = 0.4558, n = 51; 
respectively). Thus, the outer retinal thickness before the injections was not significantly 
correlated with the BCVAs at 12 months after the IVA injections. The correlations between the 
PROS length and the outer retinal thickness and CMT before the IVA injections were not 
significant ( = -0.031, P = 0.8180, n = 51;  = -0.128, P = 0.3521, n = 51, respectively). Thus, the 
PROS length and outer retinal thickness were not correlated with the CMT. 
 
We also examined the comparisons among the values of the parameters in the EZ+ group and 
the EZ- group (Table 4). In the EZ+ group, the BCVA before the IVA treatments was significantly 
better than in the EZ- group (P < 0.0001; Table 4). In addition, the BCVA at 12 months after the 
IVA injections was significantly better in the EZ+ group than in the EZ- group (P = 0.0492; Table 4). 
In the EZ+ group, the mean PROS length was significantly longer than in the EZ- group (P = 
0.0003; Table 4). Thus, the presence or absence of a disrupted EZ was associated with a longer 
or shorter PROS length. 
 
Discussion 
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The results of various country’s real-world studies on the effect of anti-VEGF therapies over a 
1-year period have been reported in eyes with DME [21-25]. However, most of the results were 
obtained from that after intravitreal ranibizumab (IVR) injections [21-25]. As far as we researched 
by Pubmed, our study is the first real-world study of the effects of 1-year IVA treatments on eyes 
with DME. When we compared to the ideal world evidence of clinical trials [7,8], the mean 
numbers of anti-VEGF injections were fewer, and the efficacy was lower in the real-world 
evidence of anti-VEGF treatment for DME. In the VISTA and VIVID studies [8], the mean number 
of IVA injections was 9 to 12 times/year, and in the REVEAL study [7], the mean number of 
ranibizumab injections was 7 to 8 times/year. On the other hand, the mean number of 
ranibizumab injections was 7 times/year in a practical study in the United Kingdom [21]. In studies 
in Denmark [22] and France [23], the mean numbers of ranibizumab injections were 5 times/year. 
In the United States [24], the mean number of anti-VEGF injections was 5.8 for the first year. In a 
study in Italy [25], the mean number of IVR injections was only 4 for a period of 18 months. In our 
study, the mean number of IVA injections was less than 4 times/year. Nevertheless, the BCVAs 
after 1 year of IVA were significantly improved compared to that at the baseline (Figure 2).  
Of course this study and the VISTA and VIVID studies are different designe, end-point , and 
different criteria, so we can not compare the results, but when we dare to do that, the changes in 
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CMT of VISTA and VIVID study is -190μm and this is good result rather than our -110μm. And 
improvement Of BCVA of VISTA and VIVID stydy is +11.7letter/year and this result may be a good 
results rather than our study.Thus, even with less frequent injections, the changes of mean BCVA 
can be significantly better. The result of clinical test is surely good, but the lower number of IVA 
injections indicates that it would be more cost effective than the higher numbers obtained from the 
clinical trials. 
 
Our results indicate that the BCVAs in eyes with DME and a SRD were improved more 
significantly than in eyes with DME without a SRD. This is consistent with our earlier short-term 
study [12], and also with Seo et al. who reported that eyes with DME and SRD required more 
frequent ranibizumab injections than eyes with DME with diffuse retinal thickening [13]. In our 
study, however, the mean number of injections in eyes with DME and a SRD was 3.9 ± 3.0 
times/year and without a SRD was 3.7 ± 2.1 times/year (P = 0.8526; Mann-Whitney U-test). The 
results of our study are consistent with a recent study that reported better visual improvement in 
eyes with DME with a SRD [14]. However, we cannot eliminate the possibility that the visual 
improvement may have been associated with a lower baseline BCVA. In this study, the baseline 
mean BCVAs in eyes with DME with SRD was 0.56 ± 0.34 logMAR units and without SRD was 
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0.32 ± 0.25 logMAR units (P = 0.0135, Mann-Whitney U-test). Although VEGF may have been 
accumulated in the fluid of the SRD and anti-VEGF agents may reduce the activity of the 
accumulated VEGF in the subretinal space [12], additional studies are needed to determine the 
efficacy of IVA in DME with and without SRD. 
 
The PROS length is defined as the distance between the EZ and the RPE line, and the length 
ranges from 25 µm to 63 µm in the macula area in histological measurements in humans [26,27]. 
In our cohort, the mean PROS length was 57.8 ± 10.0 µm which is comparable to the histological 
measurements [26, 27]. Our results indicated that the PROS length before treatment was 
significantly correlated with the BCVAs 12 months after IVA treatment. This means that shorter 
PROS lengths are correlated with poorer visual acuities. In addition, our findings showed that a 
shorter PROS length was associated with a disruption of the EZ line (Table 4). The EZ is useful for 
evaluating the integrity of the foveal photoreceptor and is significantly correlated with the final 
visual acuity in eyes with DME [15,16]. A recent study suggests that PROS length is a predictive 
factor for the visual outcome after anti-VEGF injections for eyes with retinal vein occlusion [28]. 
Our results showed that the PROS length can be used as a predictive marker for the visual 
outcome at 12 months after IVA injections in eyes with DME. On the other hand, the outer retinal 
 15 
thickness is not correlated with the visual acuity at any time during the study. The outer retinal 
thickness includes not only the PROS length but also the nuclei and axons of the photoreceptors. 
Thus, changes of PROS length could be masked by the other cellular components in the outer 
retinal thickness.  
 
CMT was not correlated with neither visual acuities nor PROS length. In some cases, the changes 
of CMT is not paralleled with the changes of BCVAs. For example, CMT was decreasing in the 
SRD- group at 3 months after IVA injection compared with 1 month after IVA, but the BCVAs were 
worsening. That is why we focused on the microstructures of the fovea for the evaluation of visual 
function in eyes with DME in this study. Our results suggest that only the outer segments of the 
photoreceptors are important for predicting the visual acuity after IVA treatment in eyes with DME. 
 
This study has limitations. This was a retrospective study on a small number of eyes. In addition, 
not all patients were treatment-naïve because of the retrospective nature of this study. Thus, the 
conclusion of this study should be interpreted with caution. Further large prospective studies are 
needed to examine the efficacy of IVA in eyes with DME. 
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In conclusion, a lower number of IVA injections can significantly improve the BCVA and reduce the 
CMT in eyes with DME. The effectiveness of IVA is not dependent on the presence or absence of 
a SRD. The PROS length is a predictive factor for visual outcome 12 months after IVA therapy in 
eyes with DME.  
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Table 1. Clinical data and features. 
Age (years) 64.7 ± 10.8 
Gender (men : women) 27 : 24 
HbA1c (%) 7.8 ± 1.7 
DM duration (years) 8.6 ± 9.5 
BCVA (logMAR units before) 0.39 ± 0.30 
CMT (m; before) 489.6 ± 106.8 
Injection times 3.8 ± 2.4 
SRD (SRD+ : SRD-) 16 : 35 
Pretreatment of IVR/IVB (eyes) 
               PC (eyes) 
               STTA (eyes) 
27 
34 
38 
Additional treatment STTA 3, PC 5, PPV 1 
Length from RPE to EZ line (m) 57.8 ± 10.0 
Length from RPE to ELM line (m) 82.6 ± 6.3 
Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness; SRD, serous 
retinal detachment; IVR, intravitreal ranibizumab injection; IVB, intravitreal bevacizumab injection; 
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PC, photocoagulation; STTA, sub-Tenon’s capsule triamcinolone acetonide; RPE, retinal pigment 
epithelium; EZ, ellipsoid zone; ELM, external limiting membrane. 
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Table 2. The real values of BCVA (logMAR VA) before and after IVA treatment in eyes with (SRD+) 
and without (SRD-) a serous retinal detachment. 
Before IVA (total) 0.39±0.30 
1M after IVA 0.32±0.29 
3M after IVA 0.34±0.33 
6M after IVA 0.32±0.31 
12M after IVA 0.30±0.28 
Before IVA (SRD+) 0.53±0.33 
1M after IVA 0.43±0.34 
3M after IVA 0.39±0.36 
6M after IVA 0.36±0.34 
12M after IVA 0.36±0.30 
Before IVA (SRD-) 0.32±0.25 
1M after IVA 0.27±0.25 
3M after IVA 0.30±0.31 
6M after IVA 0.30±0.28 
12M after IVA 0.28±0.27 
 27 
Abbreviations: BCVA, best-corrected visual acuity; IVA, intravitreal aflibercept injection. 
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Table 3. The real values of CMT before and after IVA treatment in eyes with (SRD+) and without 
(SRD-) a serous retinal detachment. 
Before IVA (m; total) 489.6±106.8 
1M after IVA 370.3±96.1 
3M after IVA 379.0±106.4 
6M after IVA 388.4±113.1 
12M after IVA 386.6±116.5 
Before IVA (m; SRD+) 536.3±109.4 
1M after IVA 386.0±136.1 
3M after IVA 413.4±130.1 
6M after IVA 417.2±148.0 
12M after IVA 387.6±159.3 
Before IVA (m; SRD-) 464.1±95.0 
1M after IVA 363.0±64.7 
3M after IVA 359.0±86.4 
6M after IVA 376.9±87.1 
12M after IVA 383.2±88.8 
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Abbreviations: CMT, central macular thickness; IVA, intravitreal aflibercept injection. 
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Table 4. Comparisons of parameters in EZ+ and EZ- eyes with DME.  
 EZ+ EZ- P values 
BCVA (logMAR units; before) 0.24 ± 0.20 0.60 ± 0.28 P<0.0001 
BCVA 12M after IVA (logMAR units) 0.15 ± 0.20 0.25 ± 0.21 P=0.0492 
CMT (m; before) 466 ± 107 521 ± 100 P=0.0705 
CMT 12M after IVA (m) 365 ± 81 415 ± 149 P=0.3134 
Mean PROS length (m) 62.1 ± 8.3 52.1 ± 9.5 P=0.0003 
Mean outer retinal thickness (m) 82.9 ± 4.5 82.1 ± 8.2 P=0.4285 
Abbreviations: EZ, ellipsoid zone; BCVA, best-corrected visual acuity; CMT, central macular 
thickness; IVA, intravitreal aflibercept injection; PROS, photoreceptor outer segment.  
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Figure legends 
FIGURE 1. Spectral-domain optical coherence tomographic (SD-OCT) image of a retina showing 
how the outer retinal thickness and PROS length were measured. The outer retinal thickness was 
measured from the external limiting membrane (ELM) to the outer border of the highly reflective 
retinal pigment epithelium (RPE) line. The photoreceptor outer segment (PROS) length was 
measured from the ellipsoid zone (EZ) to the RPE line. 
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FIGURE 2. Changes in the mean best-corrected visual acuity (BCVA) expressed in logarithm of 
the minimum angle of resolution (logMAR) units before and after an intravitreal aflibercept (IVA) 
injection in eyes with a serous retinal detachment (SRD+) or without a SRD (SRD-). Data are 
expressed as the means ± standard error of the means (SEMs). *P <0.05, **P <0.01 relative to the 
baseline best-corrected visual acuity (BCVA). 
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FIGURE 3. Changes of the mean central macular thickness (CMT) before and after IVA injections 
in eyes with or without a SRD. Data are expressed as the means ± SEMs. **P <0.01 relative to the 
baseline CMT.  
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